|
Back to Home » November 2022 News » BerGenBio reports third quarter 2022 financial results and provides business update |
BerGenBio reports third quarter 2022 financial results and provides business update |
November 15, 2022
- Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients - - Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations - - Strengthened financial position with support from largest shareholder - BERGEN, Norway, Nov. 15, 2022...
Source URL: https://www.prnewswire.com:443/news-releases/bergenbio-reports-third-quarter-2022-financial-results-and-provides-business-update-301677958.html
|
|
|
|
